Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1365-1368

  Khlif, Mohamed ^a   Bogreau, Hervé ^b   Michel Nguyen, Annie ^c   Ayadi, Ali ^a   Ranque, Stéphane ^c  

^a UNIVERSITY OF SFAX   (Tunisia)

^b SERVICE DE SANTÉ DES ARMÉES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; CDC3 PROTEIN; EF3 PROTEIN; FUNGAL PROTEIN; HIS3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DRUG EXPOSURE; FUNGUS GROWTH; FUNGUS ISOLATION; GENE LOCUS; GENETIC VARIABILITY; GENOMICS; GENOTYPE; IN VITRO STUDY; MICROSATELLITE MARKER; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; ECHINOCANDINS; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSATELLITE REPEATS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 77149129251     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00530-09     Document Type: Article

References (31)

1. Arikan, S., B. Sancak, and G. Hascelik. 2005. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Med. Mycol. 43:171-178.
2. Baixench, M. T., N. Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, S. Ramires, C. Piketty, and E. Dannaoui. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
3. Belkhir, K., P. Borsa, L. Chikhi, N. Raufaste, and F. Bonhomme. 1996. GENETIX 4.05, logiciel sous Windows TM pour la génétique des populations. Laboratoire Génome, Interactions, CNRS UMR 5171, Université de Montpellier II, Montpellier, France.
4. Blignaut, E., J. Molepo, C. Pujol, D. R. Soll, and M. A. Pfaller. 2005. Clade-related amphotericin B resistance among South African Candida albicans isolates. Diagn. Microbiol. Infect. Dis. 53:29-31.
5. Botterel, F., C. Desterke, C. Costa, and S. Bretagne. 2001. Analysis of microsatellite markers of Candida albicans used for rapid typing. J. Clin. Microbiol. 39:4076-4081.
6. Chamilos, G., R. E. Lewis, N. Albert, and D. P. Kontoyiannis. 2007. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51:2257-2259.
7. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297.
8. Cowen, L. E., C. Sirjusingh, R. C. Summerbell, S. Walmsley, S. Richardson, L. M. Kohn, and J. B. Anderson. 1999. Multilocus genotypes and DNA fingerprints do not predict variation in azole resistance among clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 43:2930-2938.
9. Dodgson, A. R., K. J. Dodgson, C. Pujol, M. A. Pfaller, and D. R. Soll. 2004. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob. Agents Chemother. 48:2223-2227.
10. Eagle, H. 1948. A paradoxical zone phenomenon in the bactericidal action of penicillin in vitro. Science 107:44-45.
11. Fleischhacker, M., C. Radecke, B. Schulz, and M. Ruhnke. 2008. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur. J. Clin. Microbiol. Infect. Dis. 27:127-131.
12. Goudet, J. 2003. Fstat (Version 2.9.4), a program to estimate and test population genetics parameters. University of Lausanne, Lausanne, Switzerland. http://www2.unil.ch/popgen/softwares/fstat.htm.
13. Goudet, J., M. Raymond, T. de Meeus, and F. Rousset. 1996. Testing differentiation in diploid populations. Genetics 144:1933-1940.
14. Jacobsen, M. D., J. A. Whyte, and F. C. Odds. 2007. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob. Agents Chemother. 51:1882-1884.
15. Jain, P., Z. K. Khan, E. Bhattacharya, and S. A. Ranade. 2001. Variation in random amplified polymorphic DNA (RAPD) profiles specific to flucon-azole-resistant and -sensitive strains of Candida albicans. Diagn. Microbiol. Infect. Dis. 41:113-119.
16. Marr, K. A., T. R. Rustad, J. H. Rex, and T. C. White. 1999. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob. Agents Chemother. 43:1383-1386.
17. Odds, F. C., and M. D. Jacobsen. 2008. Multilocus sequence typing of pathogenic Candida species. Eukaryot. Cell 7:1075-1084.
18. Pujol, C., S. A. Messer, M. Pfaller, and D. R. Soll. 2003. Drug resistance is not directly affected by mating type locus zygosity in Candida albicans. Antimicrob. Agents Chemother. 47:1207-1212.
19. Pujol, C., M. Pfaller, and D. R. Soll. 2002. Ca3 fingerprinting of Candida albicans bloodstream isolates from the United States, Canada, South America, and Europe reveals a European clade. J. Clin. Microbiol. 40:2729-2740.
20. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
21. Rustad, T. R., D. A. Stevens, M. A. Pfaller, and T. C. White. 2002. Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology 148:1061-1072.
22. Sampaio, P., L. Gusmao, A. Correia, C. Alves, A. G. Rodrigues, C. Pina-Vaz, A. Amorim, and C. Pais. 2005. New microsatellite multiplex PCR for Candida albicans strain typing reveals microevolutionary changes. J. Clin. Microbiol. 43:3869-3876.
23. Soll, D. R., and C. Pujol. 2003. Candida albicans clades. FEMS Immunol. Med. Microbiol. 39:1-7.
24. Stevens, D. A. 2009. Frequency of paradoxical effect with caspofungin in Candida albicans. Eur. J. Clin. Microbiol. Infect. Dis. 29:717.
25. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
26. Stevens, D. A., M. Ichinomiya, Y. Koshi, and H. Horiuchi. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50:3160-3161.
27. Stevens, D. A., T. C. White, D. S. Perlin, and C. P. Selitrennikoff. 2005. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis. 51:173-178.
28. Tavanti, A., A. D. Davidson, E. M. Johnson, M. C. Maiden, D. J. Shaw, N. A. Gow, and F. C. Odds. 2005. Multilocus sequence typing for differentiation of strains of Candida tropicalis. J. Clin. Microbiol. 43:5593-5600.
29. Walker, L. A., C. A. Munro, I. de Bruijn, M. D. Lenardon, A. McKinnon, and N. A. R. Gow. 2008. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 4:e1000040.
30. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentrationdependent activity. J. Infect. Dis. 190:1464-1471.
31. Wiederhold, N. P., D. P. Kontoyiannis, R. A. Prince, and R. E. Lewis. 2005. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob. Agents Chemother. 49:5146-5148.